NASDAQ:DRNA - Dicerna Pharmaceuticals Stock Price, Forecast & News

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DRNA stock has increased by 1.4% and is now trading at $17.12. View which stocks have been mosted impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its quarterly earnings data on Thursday, February, 27th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.50. The biopharmaceutical company earned $7.08 million during the quarter, compared to analysts' expectations of $26.40 million. Dicerna Pharmaceuticals had a negative net margin of 503.93% and a negative return on equity of 76.93%. View Dicerna Pharmaceuticals' earnings history.

10 brokerages have issued 12 month price targets for Dicerna Pharmaceuticals' stock. Their forecasts range from $18.00 to $50.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $31.22 in the next twelve months. This suggests a possible upside of 82.4% from the stock's current price. View analysts' price targets for Dicerna Pharmaceuticals.

News stories about DRNA stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutDicerna Pharmaceuticals.

Dicerna Pharmaceuticals saw a drop in short interest in February. As of February 28th, there was short interest totaling 3,060,000 shares, a drop of 10.5% from the February 13th total of 3,420,000 shares. Based on an average trading volume of 664,300 shares, the short-interest ratio is currently 4.6 days. Approximately 6.8% of the company's shares are short sold. View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include Reata Pharmaceuticals (RETA), Amarin (AMRN), Forty Seven (FTSV), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Evotec (EVTCY), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Emergent Biosolutions (EBS), FibroGen (FGEN) and GW Pharmaceuticals PLC- (GWPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), Amarin (AMRN), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Array Biopharma (ARRY), Crispr Therapeutics (CRSP), Exelixis (EXEL) and Gilead Sciences (GILD).

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (5.96%), EcoR1 Capital LLC (5.30%), UBS Group AG (3.20%), Bridger Management LLC (2.90%), Eagle Asset Management Inc. (2.57%) and State Street Corp (2.42%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Brian K Halak, Dennis Langer, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky. View institutional ownership trends for Dicerna Pharmaceuticals.

DRNA stock was sold by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, Bridger Management LLC, EcoR1 Capital LLC, UBS Group AG, Sofinnova Investments Inc., Emerald Advisers LLC, State Street Corp, and Emerald Mutual Fund Advisers Trust. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, and Peter Kolchinsky. View insider buying and selling activity for Dicerna Pharmaceuticals.

DRNA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Driehaus Capital Management LLC, Marshall Wace LLP, Renaissance Technologies LLC, Parkman Healthcare Partners LLC, Marshall Wace North America L.P., Connor Clark & Lunn Investment Management Ltd., and Connor Clark & Lunn Investment Management Ltd.. View insider buying and selling activity for Dicerna Pharmaceuticals.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $17.12.

Dicerna Pharmaceuticals has a market capitalization of $1.26 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe. View additional information about Dicerna Pharmaceuticals.

The official website for Dicerna Pharmaceuticals is http://www.dicerna.com/.

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]